Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA.
Medical Scientist Training Program, University of Pittsburgh and Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.
World Neurosurg. 2022 Nov;167:e629-e638. doi: 10.1016/j.wneu.2022.08.068. Epub 2022 Aug 27.
While surgery is a critical treatment option for craniopharyngiomas, the optimal surgical approach remains under debate. Herein, we studied a large cohort of craniopharyngioma patients to identify predictors of endoscopic surgery (ES) and to compare survival outcomes between patients undergoing ES versus nonendoscopic surgery (NES).
The National Cancer Database was queried for patients receiving definitive surgical treatment in 2010-2016. Cox proportional hazards and propensity score-adjusted Kaplan-Meier analyses assessed mortality risk and overall survival, respectively. Predictors of surgical approach were evaluated via logistic regression.
Of 1721 patients, 508 (29.5%) underwent ES, 877 (50.9%) were female, and the average age was 41.8 ± 21.3 years. Matched ES and NES cohorts exhibited 5-year overall survival rates of 88.0% and 79.8%, respectively (P = 0.004). ES was associated with reduced mortality (Hazard Ratio = 0.634; 95% confidence interval [CI], 0.439-0.914; P = 0.015). Patients treated at academic facilities (Odds Ratio [OR] = 2.095; 95% CI, 1.529-2.904; P < 0.001) or diagnosed recently (OR = 1.132; 95% CI, 1.058-1.211; P < 0.001) were more likely to undergo ES, while those with tumor sizes >3 cm (OR = 0.604; 95% CI, 0.451-0.804; P < 0.001) or receiving adjuvant radiotherapy (OR = 0.641; 95% CI, 0.454-0.894; P = 0.010) were more likely to receive NES. Surgical inpatient stays were significantly shorter with ES compared to NES (8.0 vs. 10.5 days, P < 0.001). On linear regression, ES usage increased by 82.4% and NES usage decreased by 23.4% between 2010 and 2016 (R = 0.575, P = 0.031).
ES of craniopharyngioma was associated with reduced mortality and shorter inpatient stays compared to NES. Factors including tumor size, extent of resection, facility type, and year of diagnosis may predict receiving ES. There is a trend towards increased usage of ES for surgical management of craniopharyngiomas.
尽管手术是颅咽管瘤的重要治疗选择,但最佳手术入路仍存在争议。在此,我们研究了大量颅咽管瘤患者,以确定内镜手术(ES)的预测因素,并比较接受 ES 与非内镜手术(NES)治疗的患者的生存结局。
从 2010 年至 2016 年,国家癌症数据库查询接受确定性手术治疗的患者。使用 Cox 比例风险和倾向评分调整的 Kaplan-Meier 分析评估死亡率和总生存率。通过逻辑回归评估手术方法的预测因素。
在 1721 名患者中,508 名(29.5%)接受 ES,877 名(50.9%)为女性,平均年龄为 41.8±21.3 岁。ES 和 NES 匹配队列的 5 年总生存率分别为 88.0%和 79.8%(P=0.004)。ES 与死亡率降低相关(风险比=0.634;95%置信区间 [CI],0.439-0.914;P=0.015)。在学术机构接受治疗的患者(比值比 [OR]=2.095;95%CI,1.529-2.904;P<0.001)或最近诊断的患者(OR=1.132;95%CI,1.058-1.211;P<0.001)更有可能接受 ES,而肿瘤大小>3cm 的患者(OR=0.604;95%CI,0.451-0.804;P<0.001)或接受辅助放疗的患者(OR=0.641;95%CI,0.454-0.894;P=0.010)更有可能接受 NES。与 NES 相比,ES 的手术住院时间明显缩短(8.0 天 vs. 10.5 天,P<0.001)。在线性回归中,2010 年至 2016 年,ES 的使用率增加了 82.4%,NES 的使用率降低了 23.4%(R=0.575,P=0.031)。
与 NES 相比,颅咽管瘤的 ES 与死亡率降低和住院时间缩短相关。肿瘤大小、切除范围、机构类型和诊断年份等因素可能预测接受 ES。对于颅咽管瘤的手术治疗,ES 的使用呈上升趋势。